Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 5/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991839 | 0.80 | ADORA2A (0.46) | TLR8TLR7GCGR | |
| SCHEMBL4375162 | 0.70 | DHFR (0.49) | CYP2D6TLR8TLR7DHFRGCGR | |
| SCHEMBL4992343 | 0.68 | TLR8 (0.40) | TLR8TLR7DHFRGCGR | |
| SCHEMBL17545030 | 0.65 | DHFR (0.54) | CYP2D6TLR8TLR7DHFR | |
| SCHEMBL4988562 | 0.65 | TLR8 (0.37) | TLR8TLR7DHFRGCGR | |
| SCHEMBL3132086 | 0.65 | GAA (0.45) | — | |
| SCHEMBL3121971 | 0.65 | GAA (0.45) | — | |
| SCHEMBL174682 | 0.65 | GAA (0.45) | — | |
| SCHEMBL3135629 | 0.65 | GAA (0.45) | — | |
| SCHEMBL3125386 | 0.65 | GAA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176744-A1 | Use of 4-Aminopyrimidines for Controlling Harmful Fungi, Novel 4-Aminopyrimidines, Processes for Their Preparation and Compositions Comprising Them | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1858327-A1 | USE OF 4-AMINOPYRIMIDINES FOR THE PREVENTION OF FUNGAL PESTS NOVEL 4-AMINOPYRIMIDINES METHOD FOR PRODUCTION THEREOF AND AGENTS COMPRISING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094994-A1 | USE OF 4-AMINOPYRIMIDINES FOR THE PREVENTION OF FUNGAL PESTS NOVEL 4-AMINOPYRIMIDINES METHOD FOR PRODUCTION THEREOF AND AGENTS COMPRISING THE SAME | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176744-A1 | Use of 4-Aminopyrimidines for Controlling Harmful Fungi, Novel 4-Aminopyrimidines, Processes for Their Preparation and Compositions Comprising Them | RRM2B, CBR3, RRM2 | PDE10A 3671/4885CYP1A2 302/4885CYP2D6 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.